GFAP levels correlate with NfL, lesion load, and brain volume for both white and gray matter in progressive MS, suggesting that GFAP may be an indicator of disease progression (Axelsson et al., 2011; Ayrignac et al., 2020; Högel et al., 2020). This evidence concerns the gene NEFL and myeloid sarcoma.